Apolipoprotein E genotype and cholesterogenesis in polygenic hypercholesterolemia

Microcrystalline Chitosan is Ineffective to Decrease Plasma Lipids in both Apolipoprotein E ε4 Carriers and Non‐Carriers: A Long‐Term Placebo‐Controlled Trial in Hypercholesterolaemic Volunteers

“…There is accumulating evidence to indicate that responses to antihyperpidaemic drugs and dietary interventions are at least partly under genetic control (Miettinen et al 1988; Tikkanen et al 1990; Mänttäri et al 1991; Lehtimäki et al 1992). One of the most widely investigated and proposed candidates is apolipoprotein E genotype, which has been shown to affect also the responsibility of hypercholesterolaemic patients to the lipid‐lowering effect of drugs (Lala et al 1998; Maitland‐van der Zee et al 2002; Mooser et al 2003). Moreover, apolipoprotein E genotype affects gastrointestinal absorption and synthesis rate of cholesterol; the subjects carrying apolipoprotein E ε4 allele seem to have higher absorption efficiency and lower sythesis rate of cholesterol than non‐carriers (Kesäniemi et al 1987; Gylling et al 1995).…”